Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06361940 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

Study acronym: MAPPER
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study Identification, Study Statusv4
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Aug 2024 to Sep 30, 2024 · Site details revised · Study title revisedv3 Show 3 more changesShow less
    • Start date changed from estimate of Aug 2024 to Sep 30, 2024
    • Site details revised
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  3. Study description expanded, about 1 wordv2 See this version in full on ClinicalTrials.gov ↗
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an exploratory phase II interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for 4-12 weeks (+/- 2 weeks).
Trial Details
NCT Number NCT06361940
Lead Sponsor Medical College of Wisconsin
Conditions Breast Cancer
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov